NCT02881255 - Avoid Transvenous Leads in Appropriate Subjects | Biotech Hunter

Enrollment

544

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

January 31, 2022

Study Completion Date

February 10, 2022

Conditions

Ventricular Arrhythmia

Interventions

DEVICE

Implantable Cardioverter Defibrillator

Patients will be randomized to receive either a subcutaneous or transvenous ICD.

Trial Locations (14)

University of Calgary, Calgary

Mazankowski Alberta Heart Institute, Edmonton

St. Paul's Hospital, Vancouver

Victoria Cardiac Arrhythmia Trials Inc., Victoria

Hamilton General Hospital, Hamilton

Southlake Regional Health Centre, Newmarket

University of Ottawa Heart Institute, Ottawa

St. Michael's Hospital, Toronto

Sunnybrook Health Sciences Centre, Toronto

Toronto General Hospital, University Health Network, Toronto

IUCPQ-Universite Laval, Laval

McGill University Health Centre, Montreal

Montreal Heart Institute, Montreal

Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke